 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

WAYNE, Pa. and ROCKVILLE, Md. , Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG...

Avalo Enters into Agreement to Divest AVTX-800 Series

WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the...

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Avalo Therapeutics, Inc. (NASDAQ:AVTX  Get Free Report) was the recipient of a large drop in short interest in the month of August. As of August 15th, there was short interest totalling 957,300 shares, a drop of 10.5% from the July 31st total of 1,070,000 shares. Based on an average daily ...

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Significant Decline in Short Interest

Avalo Therapeutics, Inc. (NASDAQ:AVTX Get Free Report) saw a significant drop in short interest in August. As of August 15th, there was short interest totalling 957,300 shares, a drop of 10.5% from the July 31st total of 1,070,000 shares. Currently, 5.2% of the companys stock are short sold. Based ...

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update

Unpacking the Risks and Rewards of Investing in Avalo TherapeuticsRelated Stocks: AVTX...

Is Avalo Therapeutics (AVTX) A Hidden Gem or A Value Trap?

Avalo Therapeutics, Inc. (NASDAQ:AVTX Get Free Report) was the recipient of a significant increase in short interest in June. As of June 30th, there was short interest totalling 628,400 shares, an increase of 1,528.0% from the June 15th total of 38,600 shares. Based on an average daily trading ...

Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Grows By 1,528.0%

WAYNE, Pa. and ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will participate in the SVB Securities Therapeutics Forum being held Tuesday, July 11th Wednesday, ...

Avalo to Participate in SVB Securities Therapeutics Forum

Avalo Therapeutics, Inc. (NASDAQ:AVTX Free Report) major shareholder Armistice Capital, Llc sold 2,746,138 shares of the businesss stock in a transaction on Monday, June 26th. The shares were sold at an average price of $0.61, for a total transaction of $1,675,144.18. Following the completion of the...

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Major Shareholder Armistice Capital, Llc Sells 2,746,138 Shares of Stock

AVTX-002 did not meet the primary endpoint measured by reduction in asthma related events compared to placebo, although positive trends were observed among a sub-population of patients with elevated baseline serum LIGHT levels AVTX-002 significantly reduced serum LIGHT levels for study duration ...

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

In trading on Monday, biotechnology shares were relative laggards, down on the day by about 2.7%. Helping drag down the group were shares of Avalo Therapeutics, down about 85.3% and shares of BioVie off about 19.2% on the day...

Video: Monday Sector Laggards: Biotechnology, Drugs

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Watchers	12,687
52-Wk Low	$0.0806
52-Wk High	$7.00

Market Cap	$2.5M
Volume (M)	162.66M
52-Wk High	$7.00
52-Wk Low	$0.0806

AVTX Avalo Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals